Dennis C Liotta

List of Publications by Year in Descending Order

96 papers	2,309 citations	26 h-index	44 g-index
235 ext. papers	2,675 ext. citations	6.7 avg, IF	4.8 L-index

#	Paper	IF	Citations
96	Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles.. *Journal of Medicinal Chemistry*, **2022**, 65, 4058-4084	8.3	0
95	Amino-Heterocycle Tetrahydroisoquinoline CXCR4 Antagonists with Improved ADME Profiles via Late-Stage Buchwald Couplings. *ACS Medicinal Chemistry Letters*, **2021**, 12, 1605-1612	4.3	1
94	The Negative Allosteric Modulator EU1794-4 Reduces Single-Channel Conductance and Ca Permeability of GluN1/GluN2A -Methyl-d-Aspartate Receptors. *Molecular Pharmacology*, **2021**, 99, 399-411	4.3	1
93	Distinct GluN1 and GluN2 Structural Determinants for Subunit-Selective Positive Allosteric Modulation of -Methyl-d-aspartate Receptors. *ACS Chemical Neuroscience*, **2021**, 12, 79-98	5.7	3
92	Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties. *Journal of Medicinal Chemistry*, **2021**, 64, 12917-12937	8.3	2
91	A Glutamate -Methyl-d-Aspartate (NMDA) Receptor Subunit 2B-Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use. *Journal of Pharmacology and Experimental Therapeutics*, **2021**, 379, 41-52	4.7	2
90	Negative allosteric modulation of GluN1/GluN3 NMDA receptors. *Neuropharmacology*, **2020**, 176, 108117	5.5	8
89	Discovery of Dihydropyrrolo[1,2-]pyrazin-3(4)-one-Based Second-Generation GluN2C- and GluN2D-Selective Positive Allosteric Modulators (PAMs) of the -Methyl-d-Aspartate (NMDA) Receptor. *Journal of Medicinal Chemistry*, **2020**, 63, 7569-7600	8.3	5
88	Confronting Racism in Chemistry Journals. *ACS Applied Nano Materials*, **2020**, 3, 6131-6133	5.6	
87	Confronting Racism in Chemistry Journals. *ACS Applied Polymer Materials*, **2020**, 2, 2496-2498	4.3	
86	Confronting Racism in Chemistry Journals. *Organometallics*, **2020**, 39, 2331-2333	3.8	
85	Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease. *ACS Medicinal Chemistry Letters*, **2020**, 11, 491-496	4.3	2
84	Update to Our Reader, Reviewer, and Author Communities April 2020. *Energy & Fuels*, **2020**, 34, 5107-5108	4.1	
83	Biased modulators of NMDA receptors control channel opening and ion selectivity. *Nature Chemical Biology*, **2020**, 16, 188-196	11.7	14
82	Update to Our Reader, Reviewer, and Author Communities April 2020. *Organometallics*, **2020**, 39, 1665-1666	3.8	
81	Confronting Racism in Chemistry Journals. *Journal of Chemical Health and Safety*, **2020**, 27, 198-200	1.7	
80	NMDA receptor channel gating control by the pre-M1 helix. *Journal of General Physiology*, **2020**, 152,	3.4	10

79	Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018. *Expert Opinion on Therapeutic Patents*, **2020**, 30, 87-101	6.8	17
78	Synthesis and biological evaluation of 5′-C-methyl nucleotide prodrugs for treating HCV infections. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127539	2.9	2
77	Synthesis and Antiviral Activity of a Series of 2′-Methyl-4′-thionucleoside Monophosphate Prodrugs. *Molecules*, **2020**, 25,	4.8	2
76	Accelerated Discovery of Potent Fusion Inhibitors for Respiratory Syncytial Virus. *ACS Infectious Diseases*, **2020**, 6, 922-929	5.5	4
75	Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. *ACS Medicinal Chemistry Letters*, **2019**, 10, 196-202	4.3	7
74	Structural elements of a pH-sensitive inhibitor binding site in NMDA receptors. *Nature Communications*, **2019**, 10, 321	17.4	21
73	Recent advances in the development of HBV capsid assembly modulators. *Current Opinion in Chemical Biology*, **2019**, 50, 73-79	9.7	26
72	Di-aryl Sulfonamide Motif Adds π-Stacking Bulk in Negative Allosteric Modulators of the NMDA Receptor. *ACS Medicinal Chemistry Letters*, **2019**, 10, 248-254	4.3	1
71	Tetrahydroisoquinoline CXCR4 Antagonists Adopt a Hybrid Binding Mode within the Peptide Subpocket of the CXCR4 Receptor. *ACS Medicinal Chemistry Letters*, **2019**, 10, 67-73	4.3	3
70	Development of a novel progesterone analog in the treatment of traumatic brain injury. *Neuropharmacology*, **2019**, 145, 292-298	5.5	5
69	Discovery of -Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like Properties. *ACS Medicinal Chemistry Letters*, **2018**, 9, 446-451	4.3	7
68	Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties. *Journal of Medicinal Chemistry*, **2018**, 61, 946-979	8.3	16
67	The Bioactive Protein-Ligand Conformation of GluN2C-Selective Positive Allosteric Modulators Bound to the NMDA Receptor. *Molecular Pharmacology*, **2018**, 93, 141-156	4.3	14
66	Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains. *ACS Medicinal Chemistry Letters*, **2018**, 9, 89-93	4.3	12
65	Academic Drug Development: The DRIVE Model. *ACS Medicinal Chemistry Letters*, **2018**, 9, 403-407	4.3	2
64	A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons. *ACS Chemical Neuroscience*, **2018**, 9, 306-319	5.7	30
63	A Machine Learning Approach for Predicting HIV Reverse Transcriptase Mutation Susceptibility of Biologically Active Compounds. *Journal of Chemical Information and Modeling*, **2018**, 58, 1544-1552	6.1	8
62	An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups. *ELife*, **2018**, 7,	8.9	20

61	Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. *Journal of Medicinal Chemistry*, **2018**, 61, 7168-7188	8.3	14
60	A structurally derived model of subunit-dependent NMDA receptor function. *Journal of Physiology*, **2018**, 596, 4057-4089	3.9	23
59	Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells. *Oncotarget*, **2018**, 9, 16996-17013	3.3	5
58	Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists. *ACS Medicinal Chemistry Letters*, **2018**, 9, 17-22	4.3	9
57	The GluN2B-Glu413Gly NMDA receptor variant arising from a de novo GRIN2B mutation promotes ligand-unbinding and domain opening. *Proteins: Structure, Function and Bioinformatics*, **2018**, 86, 1265-1276	4.2	11
56	Identification of Non-Nucleoside Inhibitors of the Respiratory Syncytial Virus Polymerase Complex. *Journal of Medicinal Chemistry*, **2017**, 60, 2305-2325	8.3	7
55	The Structure-Activity Relationship of a Tetrahydroisoquinoline Class of N-Methyl-d-Aspartate Receptor Modulators that Potentiates GluN2B-Containing N-Methyl-d-Aspartate Receptors. *Journal of Medicinal Chemistry*, **2017**, 60, 5556-5585	8.3	14
54	GluN2D-Containing N-methyl-d-Aspartate Receptors Mediate Synaptic Transmission in Hippocampal Interneurons and Regulate Interneuron Activity. *Molecular Pharmacology*, **2016**, 90, 689-702	4.3	53
53	Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity. *Journal of Medicinal Chemistry*, **2016**, 59, 7097-110	8.3	10
52	CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. *Expert Opinion on Investigational Drugs*, **2016**, 25, 1377-1392	5.9	24
51	Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release. *Journal of Medicinal Chemistry*, **2016**, 59, 10244-10252	8.3	7
50	Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats. *Neuropharmacology*, **2016**, 109, 148-158	5.5	8
49	Discovery of a Fluorinated Enigmol Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties. *ACS Medicinal Chemistry Letters*, **2016**, 7, 537-42	4.3	14
48	In Vitro Metabolic Stability and in Vivo Biodistribution of 3-Methyl-4-furoxancarbaldehyde Using PET Imaging in Rats. *ACS Medicinal Chemistry Letters*, **2016**, 7, 563-7	4.3	10
47	Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC). *Accounts of Chemical Research*, **2016**, 49, 2091-2098	24.3	18
46	Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects. *Neuron*, **2015**, 85, 1305-1318	13.9	44
45	Chloride is an Agonist of Group II and III Metabotropic Glutamate Receptors. *Molecular Pharmacology*, **2015**, 88, 450-9	4.3	9
44	Discovery of novel N-aryl piperazine CXCR4 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 4950-4955	2.9	17

43	Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase. *ACS Medicinal Chemistry Letters*, **2015**, 6, 753-7	4.3	34
42	A novel class of negative allosteric modulators of NMDA receptor function. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 5583-8	2.9	12
41	Structural analysis of CXCR4 - Antagonist interactions using saturation-transfer double-difference NMR. *Biochemical and Biophysical Research Communications*, **2015**, 466, 28-32	3.4	9
40	One-pot transformation of esters to analytically pure ketones: methodology and application in process development. *Tetrahedron Letters*, **2015**, 56, 3005-3007	2	3
39	Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of Mycobacterium tuberculosis. *European Journal of Medicinal Chemistry*, **2015**, 92, 693-9	6.8	55
38	Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators. *Journal of Medicinal Chemistry*, **2014**, 57, 2334-56	8.3	36
37	Group A streptococcus inhibitors by high-throughput virtual screening. *European Journal of Medicinal Chemistry*, **2014**, 82, 120-6	6.8	0
36	Autophagy and apoptosis in hepatocellular carcinoma induced by EF25-(GSH)2: a novel curcumin analog. *PLoS ONE*, **2014**, 9, e107876	3.7	37
35	Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator. *Molecular Pharmacology*, **2014**, 86, 548-60	4.3	55
34	Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure. *ChemBioChem*, **2014**, 15, 1614-20	3.8	20
33	NMDA receptor modulators: an updated patent review (2013-2014). *Expert Opinion on Therapeutic Patents*, **2014**, 24, 1349-66	6.8	29
32	Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastases. *Journal of Drug Delivery*, **2014**, 2014, 865732	2.3	8
31	Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists. *Journal of Medicinal Chemistry*, **2013**, 56, 6434-56	8.3	39
30	Discovery of tetrahydroisoquinoline-based CXCR4 antagonists. *ACS Medicinal Chemistry Letters*, **2013**, 4, 1025-30	4.3	46
29	Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptors. *Journal of Medicinal Chemistry*, **2013**, 56, 5351-81	8.3	42
28	Water-soluble progesterone analogues are effective, injectable treatments in animal models of traumatic brain injury. *ACS Medicinal Chemistry Letters*, **2012**, 3, 362-6	4.3	7
27	Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors. *ACS Medicinal Chemistry Letters*, **2012**, 3, 470-5	4.3	30
26	Sphingolipid analogues inhibit development of malaria parasites. *ACS Medicinal Chemistry Letters*, **2012**, 3, 43-7	4.3	6

25	Novel NMDA receptor modulators: an update. *Expert Opinion on Therapeutic Patents*, **2012**, 22, 1337-52	6.8	62
24	Emergence of small-molecule CXCR4 antagonists as novel immune and hematopoietic system regulatory agents. *Drug Development Research*, **2011**, 72, 598-602	5.1	6
23	Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer. *ACS Medicinal Chemistry Letters*, **2011**, 2, 438-43	4.3	23
22	Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. *Molecular Pharmacology*, **2011**, 80, 782-95	4.3	76
21	A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. *Nature Communications*, **2010**, 1, 90	17.4	121
20	Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists. *Journal of Medicinal Chemistry*, **2010**, 53, 5476-90	8.3	76
19	Recent patents regarding the discovery of small molecule CXCR4 antagonists. *Expert Opinion on Therapeutic Patents*, **2009**, 19, 23-38	6.8	29
18	Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 6463-80	3.4	30
17	Synergistic Anticancer Potential of the Combination of the Novel Curcumin Analog EF24 and p38 MAPK Inhibitors. *FASEB Journal*, **2008**, 22, 1136.16	0.9	
16	Discovery of small molecule CXCR4 antagonists. *Journal of Medicinal Chemistry*, **2007**, 50, 5655-64	8.3	96
15	Synthesis of enantiomerically pure D-FDOC, an anti-HIV agent. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 4991-4	2.9	6
14	Amyloid Structure: Models and Theoretical Considerations in Fibrous Aggregates. *Journal of the Chinese Chemical Society*, **2002**, 49, 459-466	1.5	10
13	Chemical synthesis and biological evaluation of cis- and trans-12,13-cyclopropyl and 12,13-cyclobutyl epothilones and related pyridine side chain analogues. *Journal of the American Chemical Society*, **2001**, 123, 9313-23	16.4	188
12	Total synthesis of SR 121463 A, a highly potent and selective vasopressin v(2) receptor antagonist. *Journal of Organic Chemistry*, **2001**, 66, 3653-61	4.2	120
11	The oxetane ring in taxol. *Journal of Organic Chemistry*, **2000**, 65, 1059-68	4.2	72
10	Recent Reviews. 49. *Journal of Organic Chemistry*, **1998**, 63, 4857-4864	4.2	
9	Suppression of aberrant colonic crypt foci by synthetic sphingomyelins with saturated or unsaturated sphingoid base backbones. *Nutrition and Cancer*, **1997**, 28, 81-5	2.8	68
8	A General Synthetic Method of 5-Carboranyluracil Nucleosides with Potential Antiviral Activity and use in Neutron Capture Therapy. *Nucleosides & Nucleotides*, **1997**, 16, 2133-2150		9

7	Recent Reviews. 45. *Journal of Organic Chemistry*, **1997**, 62, 4886-4894	4.2	
6	Recent Reviews. 40. *Journal of Organic Chemistry*, **1996**, 61, 2572-2580	4.2	
5	Recent Reviews. 39. *Journal of Organic Chemistry*, **1996**, 61, 418-426	4.2	
4	Reactions involving selenium metal as an electrophile: Scope and limitations of the enolate-selenolate transformation. *Heteroatom Chemistry*, **1990**, 1, 141-149	1.2	3
3	Triene Cyclizations. The Total Synthesis of Pallescensin A. *Synthetic Communications*, **1987**, 17, 1655-1665	1.7	15
2	Comparison of collisional activation spectra of some positive ions produced both by charge reversal of negative ions and by decomposition of positive ions. *Organic Mass Spectrometry*, **1982**, 17, 607-611		10
1	A General Synthesis of 2-Phenylselenenylenones. The Reaction of Unsaturated Ketones with a Phenylselenenyl Chloride/Pyridine Complex. *Synthetic Communications*, **1979**, 9, 697-703	1.7	26